RxDoctor Payments Data

Marie Bentsianov, MD

Nephrology · Brooklyn, NYNPI 1285631101

Payments from drug & device makers

$32,500in general payments, 2019–2025

Across 529 payments — averaging $61.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$21K
  • AstraZeneca$1K
  • Amgen$1K
  • AbbVie$1K
  • Optinose US, Inc.$973
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$863
  • plus $6K from 43 others

What the payments were for

  • Speaking & faculty fees$19,68761%
  • Food & beverage$12,33038%
  • Education$4831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,500 in reported general payments places this provider in the 85th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$628,635
Medicare patients
585
Services billed
5,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol188$189,763
EliquisApixaban150$133,075
ProcritEpoetin Alfa50$113,944
JardianceEmpagliflozin94$111,383
CreonLipase/Protease/Amylase58$110,723
Diclofenac Sodium174$99,473
ZenpepLipase/Protease/Amylase57$97,801
LinzessLinaclotide136$87,523
TrulicityDulaglutide66$86,296
VascepaIcosapent Ethyl177$69,458
RayaldeeCalcifediol39$64,178
EntrestoSacubitril/Valsartan72$55,843
LokelmaSodium Zirconium Cyclosilicate47$50,769
KerendiaFinerenone47$42,845
OzempicSemaglutide29$38,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,326$240,532235 claims
AbbVieCreon, Linzess, Ubrelvy$1,100$213,332208 claims
Boehringer IngelheimJardiance, Tradjenta$660$140,227129 claims
PfizerEliquis$77$133,075150 claims
Lilly USA, LLCTrulicity, Mounjaro$136$120,37796 claims
Aimmune Therapeutics, Inc.Zenpep$23$97,80157 claims
OPKO Pharmaceuticals, LLCRayaldee$566$64,17839 claims
Novo NordiskOzempic, Rybelsus$608$56,93948 claims
NovartisEntresto$556$55,84372 claims
MerckJanumet, Januvia$15$44,41447 claims
BayerKerendia$20,616$42,84547 claims
GSKBreo Ellipta, Trelegy Ellipta$192$24,38844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 nephrology providers in New York.

Other nephrology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →